Skip to main content
NCBI home page
Nucleic Acids Research logoLink to Nucleic Acids Research
. 1996 Aug 1;24(15):2936–2941. doi: 10.1093/nar/24.15.2936

Effects of oligonucleotide length, mismatches and mRNA levels on C-5 propyne-modified antisense potency.

W M Flanagan 1, A Kothavale 1, R W Wagner 1
PMCID: PMC146034  PMID: 8760877

Abstract

To understand the parameters required for designing potent and specific antisense C-5 propynyl-pyrimidine-2'-deoxyphosphorothioate-modified oligonucleotides (C-5 propyne ONs), we have utilized a HeLa line that stably expresses luciferase under tight control of a tetracycline-responsive promoter. Using this sensitive and regulatable cell-based system we have identified five distinct antisense ONs targeting luciferase and have investigated the role that ON length, target mismatches, compound stability and intracellular RNA levels play in affecting antisense potency. We demonstrate that C-5 propyne ONs as short as 11 bases retained 66% of the potency demonstrated by the parent 15 base compound, that a one base internal mismatch between the antisense ON and the luciferase target reduced the potency of the antisense ON by 43% and two or more mismatches completely inactivated the antisense ON and that C-5 propyne ONs have a biologically active half-life in tissue culture of 35 h. In addition, by regulating the intracellular levels of the luciferase mRNA over 20-fold, we show that the potency of C-5 propyne ONs is unaffected by changes in the expression level of the target RNA. These data suggest that low and high copy messages can be targeted with equivalent potency using C-5 propyne ONs.

Full Text

The Full Text of this article is available as a PDF (120.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett C. F., Chiang M. Y., Chan H., Shoemaker J. E., Mirabelli C. K. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol. 1992 Jun;41(6):1023–1033. [PubMed] [Google Scholar]
  2. Black L. E., Degeorge J. J., Cavagnaro J. A., Jordan A., Ahn C. H. Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs. Antisense Res Dev. 1993 Winter;3(4):399–404. doi: 10.1089/ard.1993.3.399. [DOI] [PubMed] [Google Scholar]
  3. Black L. E., Farrelly J. G., Cavagnaro J. A., Ahn C. H., DeGeorge J. J., Taylor A. S., DeFelice A. F., Jordan A. Regulatory considerations for oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies. Antisense Res Dev. 1994 Winter;4(4):299–301. doi: 10.1089/ard.1994.4.299. [DOI] [PubMed] [Google Scholar]
  4. Coats S., Flanagan W. M., Nourse J., Roberts J. M. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science. 1996 May 10;272(5263):877–880. doi: 10.1126/science.272.5263.877. [DOI] [PubMed] [Google Scholar]
  5. Fenster S. D., Wagner R. W., Froehler B. C., Chin D. J. Inhibition of human immunodeficiency virus type-1 env expression by C-5 propyne oligonucleotides specific for Rev-response element stem-loop V. Biochemistry. 1994 Jul 19;33(28):8391–8398. doi: 10.1021/bi00194a002. [DOI] [PubMed] [Google Scholar]
  6. Fisher T. L., Terhorst T., Cao X., Wagner R. W. Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells. Nucleic Acids Res. 1993 Aug 11;21(16):3857–3865. doi: 10.1093/nar/21.16.3857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fulton R., Van Ness B. Luminescent reporter gene assays for luciferase and beta-galactosidase using a liquid scintillation counter. Biotechniques. 1993 May;14(5):762–763. [PubMed] [Google Scholar]
  8. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5547–5551. doi: 10.1073/pnas.89.12.5547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gura T. Antisense has growing pains. Science. 1995 Oct 27;270(5236):575–577. doi: 10.1126/science.270.5236.575. [DOI] [PubMed] [Google Scholar]
  10. Krieg A. M., Yi A. K., Matson S., Waldschmidt T. J., Bishop G. A., Teasdale R., Koretzky G. A., Klinman D. M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995 Apr 6;374(6522):546–549. doi: 10.1038/374546a0. [DOI] [PubMed] [Google Scholar]
  11. Lewis J. G., Lin K. Y., Kothavale A., Flanagan W. M., Matteucci M. D., DePrince R. B., Mook R. A., Jr, Hendren R. W., Wagner R. W. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3176–3181. doi: 10.1073/pnas.93.8.3176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Milligan J. F., Matteucci M. D., Martin J. C. Current concepts in antisense drug design. J Med Chem. 1993 Jul 9;36(14):1923–1937. doi: 10.1021/jm00066a001. [DOI] [PubMed] [Google Scholar]
  13. Monia B. P., Johnston J. F., Ecker D. J., Zounes M. A., Lima W. F., Freier S. M. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J Biol Chem. 1992 Oct 5;267(28):19954–19962. [PubMed] [Google Scholar]
  14. Moulds C., Lewis J. G., Froehler B. C., Grant D., Huang T., Milligan J. F., Matteucci M. D., Wagner R. W. Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides. Biochemistry. 1995 Apr 18;34(15):5044–5053. doi: 10.1021/bi00015a015. [DOI] [PubMed] [Google Scholar]
  15. Rosolen A., Kyle E., Chavany C., Bergan R., Kalman E. T., Crouch R., Neckers L. Effect of over-expression of bacterial ribonuclease H on the utility of antisense MYC oligodeoxynucleotides in the monocytic leukemia cell line U937. Biochimie. 1993;75(1-2):79–87. doi: 10.1016/0300-9084(93)90028-q. [DOI] [PubMed] [Google Scholar]
  16. Stein C. A., Cheng Y. C. Antisense oligonucleotides as therapeutic agents--is the bullet really magical? Science. 1993 Aug 20;261(5124):1004–1012. doi: 10.1126/science.8351515. [DOI] [PubMed] [Google Scholar]
  17. Stein C. A. Does antisense exist? Nat Med. 1995 Nov;1(11):1119–1121. doi: 10.1038/nm1195-1119. [DOI] [PubMed] [Google Scholar]
  18. Wagner R. W. Gene inhibition using antisense oligodeoxynucleotides. Nature. 1994 Nov 24;372(6504):333–335. doi: 10.1038/372333a0. [DOI] [PubMed] [Google Scholar]
  19. Wagner R. W., Matteucci M. D., Lewis J. G., Gutierrez A. J., Moulds C., Froehler B. C. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science. 1993 Jun 4;260(5113):1510–1513. doi: 10.1126/science.7684856. [DOI] [PubMed] [Google Scholar]
  20. Wagner R. W. The state of the art in antisense research. Nat Med. 1995 Nov;1(11):1116–1118. doi: 10.1038/nm1195-1116. [DOI] [PubMed] [Google Scholar]
  21. de Wet J. R., Wood K. V., DeLuca M., Helinski D. R., Subramani S. Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol. 1987 Feb;7(2):725–737. doi: 10.1128/mcb.7.2.725. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Nucleic Acids Research are provided here courtesy of Oxford University Press

RESOURCES